AstraZeneca purchases remaining rights to SynBio's GPC3 armored CAR-T therapy in China

Xibiman Biotech announced that AstraZeneca will acquire the remaining 50% stake of its GPC3 armored CAR-T therapy C-CAR031 in China. AstraZeneca will have exclusive rights to develop, manufacture, and commercialize C-CAR031 globally. According to the agreement, Xibiman will receive up to $630 million from AstraZeneca, including an upfront payment for the GPC3 project in China and milestone payments for development, regulatory, and sales. Previously, AstraZeneca had agreed with Xibiman to have rights to develop, manufacture, and commercialize C-CAR031 outside of China.